Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29930602 | 1.00 | ALDH1A1 (0.48) | ALDH1A1ALOX15HTTSMN1; SMN2LMNA | |
| SCHEMBL6789666 | 0.85 | ALDH1A1 (0.46) | ALDH1A1ALOX15HTTSMN1; SMN2LMNA | |
| SCHEMBL11212937 | 0.84 | HTT (0.49) | ALDH1A1HTTSMN1; SMN2LMNAMAPT | |
| SCHEMBL28288941 | 0.84 | ALDH1A1 (0.42) | ALDH1A1ALOX15HTTSMN1; SMN2LMNA | |
| SCHEMBL975946 | 0.82 | KDM4E (0.55) | ALDH1A1ALOX15HTTSMN1; SMN2LMNA | |
| SCHEMBL1286684 | 0.81 | IRAK4 (0.53) | ALDH1A1HTTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL1655964 | 0.81 | IRAK4 (0.68) | ALDH1A1HTTSMN1; SMN2LMNAMAPT | |
| SCHEMBL2154267 | 0.81 | IRAK4 (0.68) | ALDH1A1ALOX15LMNAKDM4EKMT2A | |
| SCHEMBL22987538 | 0.80 | CTSD (0.62) | ALDH1A1HTTSMN1; SMN2LMNAMAPT | |
| SCHEMBL29646356 | 0.80 | CTSD (0.62) | ALDH1A1HTTSMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103304475-A | Benzoic amide compound as well as preparation method and application thereof | HUNAN QIANJIN XIANGJIANG PHARM CO LTD | 2013-09-18 | — | — | CN | claimed |
| JP-4742026-B2 | — | — | 2011-08-10 | — | — | JP | claimed |
| EP-1606261-A1 | NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST | ALTANA Pharma AG (DE) | 2005-12-21 | — | — | EP | claimed |
| WO-2004080967-A1 | NOVEL PROCESS FOR THE PREPARATION OF ROFLUMILAST | ALTANA PHARMA AG (DE) | 2004-09-23 | — | — | WO | claimed |
| EP-0639559-B1 | Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines | ROHM & HAAS (US) | 1997-10-15 | — | — | EP | claimed |
| EP-0639559-A1 | Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines | ROHM AND HAAS COMPANY (US) | 1995-02-22 | — | — | EP | claimed |
| EP-4085056-A1 | POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER | Berg LLC (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-115210229-A | Polycyclic amides as UBE2K modulators for the treatment of cancer | 博格有限责任公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| CN-103232390-B | Refining method for high-purity roflumilast | CHENGDU HEXUN PHARMACEUTICAL CO LTD | 2014-06-11 | — | — | CN | disclosed |
| CN-103304475-A | Benzoic amide compound as well as preparation method and application thereof | HUNAN QIANJIN XIANGJIANG PHARM CO LTD | 2013-09-18 | — | — | CN | disclosed |
| CN-103232390-A | Refining method for high-purity roflumilast | CHENGDU HEXUN PHARMACEUTICAL CO LTD | 2013-08-07 | — | — | CN | disclosed |
| CN-1050599-C | Preparation of 1,2-diacyl-2-(T-alkyl) hydrazines | ROHM & HAAS (US) | 2000-03-22 | — | — | CN | disclosed |
| EP-0639559-B1 | Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines | ROHM & HAAS (US) | 1997-10-15 | — | — | EP | disclosed |
| CN-1109049-A | Preparation of 1,2-diacyl-2-(T-alkyl) hydrazines | ROHM & HAAS (US) | 1995-09-27 | — | — | CN | disclosed |
| EP-0639559-A1 | Preparation of 1,2-diacyl-2-(t-alkyl)hydrazines | ROHM AND HAAS COMPANY (US) | 1995-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091447-B2 | UBE2K modulators and methods for their use | UBE2N, UBE2B, UBE2E1 | ALDH1A1 1803/4885ALOX15 3002/4885HTT 1708/4885 |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | ALDH1A1 1803/4885ALOX15 3002/4885HTT 1708/4885 |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | ALDH1A1 1803/4885ALOX15 3002/4885HTT 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.